We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Lonza exits both softgels and liquid-filled hard capsules and NextPharma plans to broaden its technology offering into lipid based finished dosage forms.
Lonza and NextPharma have formed an agreement for the potential sale of Lonza's Ploermel, France and Edinburgh, UK sites, subject to relevant conditions and regulatory approvals.